Investigational Site Number :3800006

Naples 80138

1 studies enrolling now · 6 studies all time

What they study most

Breast Cancer, Immune Thrombocytopenia, Non-small Cell Lung Cancer, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis, Prostate Cancer, Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis

Studies at this site

• Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment — Recruiting now
• A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. — Running, not enrolling
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) — Completed
• Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer — Stopped early
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) — Completed
• Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies — Stopped early